Overview

Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis

Status:
Active, not recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to observe the long-term safety of filgotinib in adults who have completed or met protocol specified efficacy discontinuation criteria in a prior Gilead-sponsored filgotinib treatment study in ulcerative colitis (UC).
Phase:
Phase 3
Details
Lead Sponsor:
Gilead Sciences
Collaborator:
Galapagos NV